Amarin Corp. ADR Stock
€0.83
Your prediction
Amarin Corp. ADR Stock
Amarin Corporation plc (Symbol AMRN) is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product, Vascepa, is a prescription medication that has been approved by the US FDA for use as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa has also shown to reduce the risk of cardiovascular events such as heart attack and stroke in patients with elevated cardiovascular risk. As a listed company, Amarin is publicly traded on the NASDAQ stock exchange and has a market capitalization of approximately $5 billion as of August 2021.
Pros and Cons of Amarin Corp. ADR in the next few years
Pros
Cons
Performance of Amarin Corp. ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Amarin Corp. ADR | -0.610% | -4.624% | 3.125% | -30.672% | 1.227% | -80.542% | -95.015% |
| Genus plc | 1.530% | -1.010% | -5.222% | -36.364% | -21.158% | -67.059% | -26.482% |
| Sage Therapeutics Inc. | 0.780% | 2.673% | -32.022% | -71.991% | -39.500% | -80.824% | - |
| Novocure Ltd | 2.030% | -0.177% | -7.436% | -80.306% | -21.086% | -93.202% | - |
Comments
News
Why Amarin Stock Was Rocketing Higher on Wednesday
Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Amarin Stock Skyrocketed Today
Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization